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Toll-like receptors (TLRs) can sense a variety 
of microbial products such as microbial mem-
brane lipids or nucleic acids. Cell-surface TLR 
dimers including TLR4/MD-2, TLR1/2, and 
TLR6/2 recognize microbial membrane lipids, 
whereas TLR3, 7, 8, and 9 reside in intracellu-
lar organelles and recognize microbial nucleic 
acids (1, 2). Although membrane lipids like lipo-
polysaccharides or lipopeptides are structur-
ally unique to microbes, microbial nucleic acids 
share the basic structure with host-derived 
nucleic acids. Indeed, TLR9 is able to respond 
to mammalian DNA if expressed on the cell 
surface  (3).  TLR7  also  responds  to  host- 
derived, single-stranded RNA (4). Given the 
potential  autoreactivity,  nucleic  acid–sensing 
TLR7/9 have to be tightly controlled to avoid 
autoimmune reaction. Nucleic acid sensing in 
endolysosomes rather than on the cell surface is 
thought to be a safety mechanism avoiding re-
sponse to self–nucleic acid, because self–nucleic 
acids are rapidly degraded before reaching en-
dolysosomes (3). Viral nucleic acid is, on the 
other hand, protected by capsid proteins and 
able to reach endolysosomes.
Self-derived nucleic acids, however, may 
reach endolysosomes in an inflammatory or auto-
immune situation, where a variety of nucleic 
acid–binding proteins like autoantibodies, anti-
microbial peptides, and HMGB-1 (5–7) are com-
plexed with host nucleic acids. These complexes 
are resistant to degradation, reach endolysosomes, 
and stimulate TLR7 and 9. To avoid unneces-
sary stimulation of TLR7 and 9, another safety 
mechanism is working that TLR7 and 9 reside 
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Toll-like receptors (TLRs) 3, 7, and 9 recognize microbial nucleic acids in endolysosomes 
and initiate innate and adaptive immune responses. TLR7/9 in dendritic cells (DCs) also 
respond to self-derived RNA/DNA, respectively, and drive autoantibody production. Remark-
ably, TLR7 and 9 appear to have mutually opposing, pathogenic or protective, impacts on 
lupus nephritis in MRL/lpr mice. Little is known, however, about the contrasting relation-
ship between TLR7 and 9. We show that TLR7 and 9 are inversely linked by Unc93B1, a 
multiple membrane-spanning endoplasmic reticulum (ER) protein. Complementation cloning 
with a TLR7-unresponsive but TLR9-responsive cell line revealed that amino acid D34 in 
Unc93B1 repressed TLR7-mediated responses. D34A mutation rendered Unc93B1-deficient 
DCs hyperresponsive to TLR7 ligand but hyporesponsive to TLR9 ligand, with TLR3 responses 
unaltered. Unc93B1 associates with and delivers TLR7/9 from the ER to endolysosomes for 
ligand recognition. The D34A mutation up-regulates Unc93B1 association with endogenous 
TLR7 in DCs, whereas Unc93B1 association with TLR9 was down-regulated by the D34A 
mutation. Consistently, the D34A mutation up-regulated ligand-induced trafficking of 
TLR7 but down-regulated that of TLR9. Collectively, TLR response to nucleic acids in DCs is 
biased toward DNA-sensing by Unc93B1.
© 2009 Fukui et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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GFP was, however, not induced by the TLR9 ligand CpG-B 
despite expression of TLR9 (Fig. 1 A, left, blue histogram). 
Functional cloning identified cathepsin B/L as molecules able 
to confer TLR9 responsiveness on Ba/F3 cells (Fig. 1 A, 
right) (26). We next studied TLR7 responsiveness in Ba/F3 
cells. Overexpressed TLR7 failed to induce NF-B–depen-
dent GFP expression upon stimulation with a TLR7 ligand 
loxoribine in Ba/F3 cells (Fig. 1 B, left, blue histogram). 
Expression of cathepsin B/L was unable to confer TLR7 re-
sponses (Fig. 1 B, right). Therefore, we hypothesized that a 
molecule is missing in Ba/F3 cells that is required for TLR7 
but not TLR9. Functional cloning was conducted again, 
and a cDNA encoding Unc93B1 conferred TLR7 respon-
siveness on Ba/F3 cells (Fig. 1 C, middle, N83). The 
Unc93B1 cDNA obtained by complementation cloning lacked 
the 5 region up to 102 bases from the initiating codon, sug-
gesting that N-terminally truncated Unc93B1 is expressed 
from the second methionine M84 (Fig. 1 D). Expression of 
the truncated Unc93B1 (referred to as N83) was examined 
by flow cytometry and biochemical analyses of the truncated 
cDNA tagged with GFP or hemagglutinin (HA), respec-
tively, to the C terminus (Fig. S1, A and B). Expression of 
N83 protein was confirmed by both flow cytometry and 
immunoprecipitation but seemed to be lower than that of 
full-length Unc93B1, probably because of proteolytic degra-
dation (Fig. S1 B). RT-PCR analyses revealed that Unc93B1 
mRNA is expressed in Ba/F3 cells as well as in DCs and 
RAW264.7  cells  (Fig.  S1  C),  suggesting  that  full-length 
Unc93B1 endogenously expressed in Ba/F3 cells did not 
enable TLR7 response in Ba/F3 cells. Indeed, further ex-
pression of full-length Unc93B1 did not rescue TLR7 re-
sponse (Fig. 1 C, middle). These results suggest that N-ter-
minally  truncation  of  Unc93B1  is  critical  for  conferring 
TLR7 responsiveness on Ba/F3 cells.
D34 in Unc93B1 is required for repression  
of TLR7-mediated responses
A missense mutation in the Unc93B1 gene in mice abrogates 
signaling via TLR3/7/9 without compromising other TLRs 
(8). Despite the requirement for Unc93B1 in both TLR7 
and 9, functional cloning suggested that the N-terminal 83 
aa negatively regulates TLR7 but not TLR9 in Ba/F3 cells. 
To narrow down the N-terminal region critical for repress-
ing TLR7-mediated responses, we examined Unc93B1 de-
letion mutants. The mutants lacking up to N-terminal 33 aa 
(N18, N23, N30, and N33) had no effect on TLR7 
response, whereas those lacking beyond 36 aa (N36, N37, 
N55, and N83) conferred TLR7 response (Fig. S2 A). 
The mutant lacking N-terminal 155 aa was unable to confer 
TLR7 responsiveness. These mutants suggested that DEL 
(34-36) is critical for negatively regulating TLR7 responses. 
We tested the Unc93B1 mutants containing an alanine sub-
stitution at D34, E35, or both (D34A, E35A, or DE/AA). 
D34A and DE/AA but not E35A mutants conferred TLR7-
dependent GFP induction (Fig. 1 C, middle). D34 is con-
served in human Unc93B1 (Fig. S2 B) and predicted to 
in the ER and traffic to endolysosomes only upon activation. 
The TLR7/9 trafficking is controlled by Unc93B1, a mul-
titransmembrane ER-resident protein. In mice, a missense 
mutation in the Unc93b1 gene (H412R mutation) abrogates 
signaling via TLR3, 7, and 9 without compromising other 
TLRs (8). These mutant mice (3d mice) show increased sus-
ceptibility to infection by a variety of pathogens. Functional 
null mutations of Unc93B1 are responsible for herpes sim-
plex encephalitis in children (9). As in 3d mice, cells from 
Unc93B1-deficient patients are defective in signaling via the 
nucleic acid–sensing TLRs 3, 7, 8, and 9. Unc93B1 was 
shown to bind to TLR3/7/9/13 via the transmembrane do-
mains  of  the  TLRs  (10).  The  point  mutation  H412R  of 
Unc93B1 abolishes these interactions. Unc93B1 was further re-
ported to deliver TLR7/9 from the ER to endolysosomes, 
where TLR7/9 recognize their ligands (11).
Despite the fail-safe mechanisms limiting the access of 
both ligands and TLR7/9 to endolysosomes, TLR7 and 9 
predispose to autoimmune diseases. Overexpression of TLR7 
in the Yaa or transgenic mice predisposes to lupus nephritis 
(12, 13), whereas the lack of the TLR7 gene ameliorates dis-
ease progression in lupus-prone mice (14, 15). TLR9 is more 
complicated than TLR7 in its link with autoimmune disease. 
Despite the reports showing a pathogenic role for TLR9 in 
psoriasis,  lupus  nephritis,  adjuvant-induced  arthritis,  or  a 
mouse model of multiple sclerosis (16–20), opposing results 
were also described that TLR9 deficiency in autoimmune-
prone MRL/lpr mice exacerbates clinical diseases, including 
more severe glomerulonephritis, a significantly shortened life-
span, and in some models, elevated titers of autoantibodies 
reactive with RNA-associated autoantigens (14, 21). The 
disease severity and RNA-skewed autoantibody repertoire 
are reminiscent of the phenotype of Yaa autoimmune-prone 
mice in which TLR7 is overexpressed. TLR9 signaling might 
protect disease progression at least in part by antagonizing 
TLR7. Indeed, overexpression of TLR9 inhibits TLR7 (22), 
and TLR9 ligand strongly inhibited the development of in-
flammatory arthritis (23).
TLR7 and 9 are both expressed in B cells and DCs, and 
share downstream signaling pathways (24, 25). If TLR7 and 9 
work differently, TLR7 and 9 need to be coordinated in a 
single cell. The present study revealed that TLR7 and 9 are 
inversely linked by Unc93B1. Moreover, Unc93B1 biases 
DC responses toward TLR9 and against TLR7. Given the 
pathogenic and protective roles for TLR7 and 9 in lupus   
nephritis, respectively, the present study may have revealed 
another safety mechanism avoiding autoimmune diseases by 
balancing TLR7 and 9 in DCs.
RESULTS
Unc93B1 is required for TLR7-unresponsive  
and TLR9-responsive cell lines
We  previously  established  the  pro–B  cell  line  Ba/F3,  in 
which  TLR-dependent  NF-B  activation  was  easily  de-
tected by GFP induction (26). Lipid A induced GFP when 
TLR4/MD-2 was expressed (Fig. 1 A, black histogram). JEM VOL. 206, June 8, 2009 
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nously expressed in 3dDCs unlikely affects interaction be-
tween TLR3/7/9 and overexpressed Unc93B1. Retrovirus 
vector encoding WT or D34A Unc93B1-GFP was trans-
duced into 3d BM cells that were then induced to differenti-
ate into DCs by GM-CSF. All of the BM-DCs expressed the 
equivalent amount of Unc93B1-GFP, which was easily de-
tected with flow cytometry (Fig. S3). DCs were stimulated 
with a variety of TLR ligands and cytokine production was 
determined by ELISA. Lipid A–induced production of IL-12, 
RANTES, and IL-6 was equivalently induced by WTDC, 
3dDC, WT Unc93B1-3dDC, and D34A Unc93B1-3dDC 
(Fig. 2 A). Poly(I:C)-induced production of RANTES and 
IL-6 was not completely abolished in 3dDCs, which can be 
explained by the cytoplasmic RNA sensors RIG-I or MDA-5 
(Fig. 2 B, white bars) (27). TLR3-dependent poly(I:C) re-
sponses were equally rescued by WT and D34A Unc93B1 
(Fig. 2 B, blue and red bars). By sharp contrast, TLR7 ligand 
induced  much  more  pronounced  production  of  IL-12, 
RANTES, and IL-6 in D34A Unc93B1-3dDCs than in 
WTDCs or in WT Unc93B1-3dDCs (Fig. 2 C). WTDCs 
locate in the cytoplasm, whereas H412 (the position of 3d 
mutation) is in the transmembrane region of the C-terminal 
half (Fig. 1 D). The Unc93B1 mutants were also expressed 
in Ba/F3 cells expressing TLR3 or 9 as well as cathepsin B/L. 
All of the mutants able to confer TLR7 responsiveness 
(N83,  D34A,  and  DE/AA)  down-regulated  CpG-B– 
dependent GFP induction, likely through their dominant-
negative effect on endogenously expressed Unc93B1 (Fig. 1 C, 
left). TLR3-dependent responses were up-regulated by over-
expression of all of the Unc93B1 mutants as well as full-
length Unc93B1 (Fig. 1 C, right). N-terminal mutations had 
no effect on TLR3 responsiveness in Ba/F3 cells.
D34A mutation biases DC response toward TLR7  
and against TLR9
WT or D34A Unc93B1 was next expressed in BM-derived 
DCs (BM-DCs) from 3d mice harboring the H412R mis-
sense mutation (WT or D34A Unc93B1-3dDC, respec-
tively).  Given  that  H412R  mutation  abolishes  Unc93B1 
association with TLR3/7/9 (10), H412R Unc93B1 endoge-
Figure 1.  Unc93B1 is selectively required for TLR7 response. (A) Ba/F3 cells expressing TLR9, CD14/TLR4/MD-2, and NF-B–GFP (left) were further 
transfected with vectors encoding cathepsin B+L (right). These cells were left unstimulated or were stimulated for 24 h with 100 nM CpG-B or 1 µg/ml 
lipid A, as indicated. GFP induction was determined by flow cytometry. (B) Experiments were conducted as in A, except that TLR7 was expressed instead of 
TLR9, and cells were stimulated with 100 µM loxoribine or lipid A, as indicated in the figure. (C) Ba/F3 cells expressing CD14/TLR4/MD-2, NF-B–GFP, and 
cathepsin B+L were further transfected with cDNA encoding TLR9 (left), 7 (middle), or 3 (right). These cells were then transfected with full-length 
Unc93B1, or its mutants lacking the N-terminal 83 aa (N83) or containing an alanine substitution at D34, E35, or both (D34A, E35A, or DE/AA).  
GFP induction is shown in response to 1 µg/ml lipid A (black lines) or TLR3/7/9 ligand (100 nM CpG-B, 100 µM loxoribine, or 25 µg/ml poly(I:C); blue lines). 
These experiments were repeated three times, and the represented data are shown. (D) Schematic representation of Unc93B1. D34 and H412 (mutated in 
3d mice) are indicated. The second M at 84 is also shown.1342 Unc93B1 INVERSELY LINKS TOLL-LIKE RECEPTORS 7 AND 9 | Fukui et al.
mRNA up to 50% of the WTDC response, whereas D34A 
Unc93B1 conferred on 3dDC a higher induction of IFN- 
mRNA than WTDCs (Fig. 2 E). TLR9-dependent induc-
tion  of  IFN-  mRNA  in  3dDCs  was  rescued  by  WT 
Unc93B1 but not by D34A Unc93B1 (Fig. 2 E). It is possible 
that D34A Unc93B1 influences TLR7/9 responses by mod-
ulating their mRNA expression. We examined expression of 
mRNA encoding TLR3/7/8/9/13 in WTDC, 3dDC, WT 
Unc93B1-3dDC, or D34A Unc93B1-3dDC. No apparent 
change was caused by transduction of WT or D34A Unc93B1 
(Fig. S4 A). These results clearly demonstrate that 34D in 
were unable to respond at 100 µM loxoribine, as were 3dDCs, 
but D34A-3dDC was able to produce cytokines (Fig. 2 C). 
On the contrary, D34A Unc93B1 failed to rescue TLR9-
dependent production of IL-12 (p40) and IL-6 in 3dDCs 
(Fig. 2 D). For an unknown reason, RANTES production in 
3dDCs was appreciably rescued by D34A Unc93B1. Induc-
tion of IFN- mRNA was next studied by semiquantitative 
real-time RT-PCR (Fig. 2 E). No alteration was seen be-
tween WT and D34A Unc93B1 in rescuing IFN- mRNA 
induction upon stimulation with poly(I:C) in 3dDC. WT 
Unc93B1  only  partially  rescued  TLR7-dependent  IFN- 
Figure 2.  Unc93B1 D34A mutant reveals a mutually exclusive link between TLR7 and 9 in DCs. (A–D) DCs from WT mice were transduced with 
a retrovirus vector encoding GFP (WTDC; black bars). DCs from 3d mice (3dDC) were also transduced by retroviral vector encoding GFP (white bars), WT 
Unc93B1-GFP (blue bars), or D34A Unc93B1-GFP (red bars). These DCs were stimulated with (A) lipid A, (B) poly(I:C), (C) loxoribine, or (D) CpG-B at the 
indicated concentrations. Production of IL-12 (left), RANTES (middle), and IL-6 (right) was determined by ELISA. (E) To determine induction of IFN- 
mRNA, semiquantitative real-time PCR was conducted. The results were represented by mean values (A–E) with SD (A–D) from triplicate wells. These ex-
periments were repeated twice and the represented data are shown.JEM VOL. 206, June 8, 2009 
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Unc93B1 leads to DC polarization toward TLR9 over TLR7 
without influencing TLR3.
D34A mutation enhances TLR7 trafficking  
and down-regulates TLR9 trafficking
To gain insight into a mechanism differentially regulating 
TLR7 and 9 by Unc93B1, we compared the subcellular dis-
tribution of WT, D34A, or H412R (3d) Unc93B1-GFP in 
DCs (Fig. 3, A and B). These three types of Unc93B1-GFP 
all showed colocalization with an ER marker but not with a 
lysosomal marker. Unc93B1 was reported to associate with 
TLR7/9 in the ER and deliver TLR7/9 to endolysosome 
(11). The subcellular distribution of WT and D34A Unc93B1 
before and after stimulation with TLR ligands was next com-
pared by analyzing BM-DCs expressing WT Unc93B1-GFP 
and  D34A  Unc93B1-cherry  (Fig.  3  C).  Stimulation  with 
three TLR ligands all induced partial accumulation of D34A 
Unc93B1 in vesicular structure, probably endolysosomes 
(Fig. 3 C, middle). WT Unc93B1 also accumulated in vesic-
ular structure (Fig. 3 C, left). Further, the subcellular distribu-
tion of WT and D34A Unc93B1 was also indistinguishable in 
Ba/F3 cells (Fig. 4 A). These results suggest that D34A muta-
tion does not alter the subcellular distribution of Unc93B1.
Unc93B1-dependent TLR7/9 trafficking was next studied. 
TLR9- or TLR7-GFP was expressed with WT or D34A 
Unc93B1 in Ba/F3 cells. CpG-B–induced TLR9 accumula-
tion  to  endolysosomes  was  appreciably  detected  in  WT 
Unc93B1–expressing cells, but little, if any, was detected in 
D34A Unc93B1–expressing cells (Fig. 4 B). In contrast, only 
a small fraction of TLR7 showed ligand-induced traffick-
ing into endolysosomes in WT Unc93B1–expressing cells, 
whereas more TLR7 relocated into endolysosomes in D34A 
Unc93B1–expressing cells (Fig. 4 C). These results suggest 
that D34A Unc93B1 enhances TLR7 trafficking, whereas it 
down-regulates TLR9 trafficking.
D34A mutation up-regulates Unc93B1 association  
with TLR7/8/13
Considering that Unc93B1 controls TLR7/9 trafficking 
through physical association (10, 11), D34A mutation may   
influence Unc93B1 association with TLR7/9. Physical asso-
ciation between TLR3/4/7/9 and Unc93B1 was therefore 
examined. TLR3/4/7/9-flag and Unc93B1-GFP were ex-
pressed in Ba/F3 cells. Unc93B1 was immunoprecipitated, 
and coprecipitation of TLR3/4/7/9 was detected. As reported 
previously (10), TLR3/7/9, but not TLR4, was coprecipi-
tated with WT Unc93B1. The 3d mutation (H412R) com-
pletely abolished Unc93B1 association with TLR3/7/9 (Fig. 5, 
middle). In contrast, D34A Unc93B1 was indistinguishable 
from WT Unc93B1 in association with TLR3/7/9 (Fig. 5). Figure 3.  D34A mutation does not influence the subcellular dis-
tribution of Unc93B1. (A and B) WT, D34A, or H412R Unc93B1-GFP 
was expressed in DCs from 3d mice. Their subcellular distribution was 
determined by confocal microscopy (left). Cells were also stained with a 
marker locating (A) ER or (B) lysosome (center). (right) Merged images. 
(C) WT Unc93B1-GFP (left) and D34A Unc93B1-cherry (center) were co-
expressed in DCs from 3d mice. These cells were left unstimulated or 
stimulated with 5 µg/ml imiquimod, 1 µM CpG-B, or 1 µg/ml lipid A for  
3 h, as indicated in the figure. Green and red images were merged (right). 
These experiments were repeated three times and the represented images 
are shown. Bars, 5 µm.
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liquid chromatography tandem mass spectrometry (LC-MS/
MS) for a label-free semiquantitative analysis. TLR3, 7, 8,   
9, and 13 were all coprecipitated with D34A or WT Unc93B1 
(Fig. 6 A). All of the identified peptide sequences, with their 
scores and the extracted ion current (XIC) values, are shown 
in Table S1. A previous report described Unc93B1 associa-
tion with TLR3, 7, 9, and 13, but not TLR8, by using 
RAW264.7 cells (10), probably because TLR8 is not ex-
pressed in RAW cells (Fig. S4 B). The present study was 
able to show for the first time that TLR8 associates with 
Unc93B1 in DCs because TLR8 mRNA was detected in 
DCs (Fig. S4 B).
Semiquantitative analyses with the MSQuant program re-
vealed a difference between WT and D34A Unc93B1 (Fig. 6 A). 
The amount of immunoprecipitated Unc93B1 was equiva-
lent between WT and D34A Unc93B1 (1.02 in the D34A/
WT ratio). Despite that only the two peptides were identified 
from TLR9, both peptides suggested that TLR9 was copre-
cipitated much less with D34A Unc93B1 than WT Unc93B1 
(0.39).  TLR7,  8,  and  13  were  coprecipitated  more  with 
D34A Unc93B1 than WT Unc93B1 (1.73, 1.68, and 1.97, 
respectively). mRNA expression of TLR9 was equivalent to 
TLR7 or 8 in BM-DCs and was not influenced by expression 
of WT or D34A Unc93B1-GFP (Fig. S4). These results sug-
gested that D34 differentially regulates Unc93B1 association 
with TLR9 or with TLR7/8/13. The D34A/WT ratio of 
TLR3 was between TLR9 and TLR7/8/13 (Fig. 6 A).
To confirm the results with semiquantitative analysis using 
XIC-based quantification, highly accurate quantitative analy-
sis by stable isotope labeling with aa (SILAC) was conducted 
twice. In experiment 1, both arginine and lysine were labeled 
with isotopes, and only a small number of BM-DCs were ob-
tained, probably because of low concentrations of these two aa 
in culture medium. To improve cell recovery, only arginine 
was labeled in experiment 2. Although a larger number of 
BM-DCs were recovered, the number of peptides analyzed 
was reduced, probably because of inefficient labeling with 
only one isotope. Despite these results, SILAC confirmed that 
larger amounts of TLR7/8/13 are coprecipiated with D34A 
Unc93B1 than WT Unc93B1 (Fig. 6 B and Table S2). In 
contrast, SILAC failed to detect a peptide from TLR9 or 3.
TLR7/9 responses are inversely regulated by the DEL 
sequence in the N-terminal region of Unc93B1
To gain further insight into a mechanism of how the N-ter-
minal region of Unc93B1 influences Unc93B1 association 
with TLR7/8/13, we further studied the additional require-
ment for aa adjacent to D34. Given that the negative regula-
tion was abolished by the lack of the N-terminal 36 aa or 
further (Fig. S2), we focused on L36 and used two additional 
Unc93B1 mutants, L36A and DEL/AAA, in which L36 or 
DEL (34-36) was replaced with alanine, respectively. These 
mutants  together  with  WT,  D34A,  and  E35A  Unc93B1 
were expressed in BM-DCs from 3d mice. BM-DCs were 
stimulated with the indicated TLR ligands, and production 
of  IL-12  and  IL-6  was  determined  by  ELISA.  L36A  and 
TLR7 and 9 reside in the ER (11, 28), whereas TLR3 
resides outside the ER (29). TLR7/9 trafficking from the 
ER to endolysosomes is not ligand specific, because TLR7/9 
traffics to endolysosomes upon LPS stimulation (11). In in-
fection or inflammation, TLR7 may compete with TLR9 
but not with TLR3 for association with Unc93B1 in the ER. 
We hypothesized that a role for D34 would be revealed   
only in a situation where TLR7 and 9 compete for Unc93B1 
association, but not in a situation where each TLR and 
Unc93B1 were overexpressed, as in Fig. 5. To address this 
possibility, it was important to use primary DCs but not a 
cell line like RAW264.7 cells, because expression of nucleic 
acid–sensing TLRs is apparently different between RAW264.7 
cells and BM-DCs (Fig. S4 B). WT or D34A Unc93B1-
GFP was expressed in 3dDCs, which endogenously express 
TLR3, 7, 8, 9, and 13 (Fig. S4). Unc93B1 was immunopre-
cipitated, and whole immunoprecipitates were analyzed on 
Figure 4.  Differential regulation of ligand-induced TLR7/9  
trafficking by Unc93B1 (A) WT Unc93B1-GFP and D34A Unc93B1-
cherry were coexpressed in Ba/F3 cells, and live cells were imaged. 
The merged and differential interference contrast (DIC) images are shown. 
(B) Ba/F3 cells expressing cathepsin B+L and TLR9-GFP were further 
transfected with WT (left) or D34A (right) Unc93B1. These cells were left 
unstimulated (top) or stimulated with 100nM CpG-B for 60 min (bottom). 
Cells were stained with a lysosome marker. Green and red images were 
merged (left), or merged images were further imposed on DIC images 
(right). (C) TLR9-GFP in B was replaced with TLR7-GFP and 5 µg/ml im-
iquimod was used as the stimulant. These experiments were repeated four 
times and represented images are shown. Bars, 5 µm.JEM VOL. 206, June 8, 2009 
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DISCUSSION
The present study showed that the N-terminal, putatively cyto-
plasmic portion of Unc93B1 represses TLR7 responses and 
enhances TLR9 responses in BM-DCs. This conclusion is 
based on the following results. First, Unc93B1 N-terminally 
truncated or D34A mutant enables TLR7 responses in Ba/F3 
cells (Fig. 1). Second, Unc93B1 D34A mutant rendered 
Unc93B1-deficient BM-DCs hyperresponsive to TLR7 li-
gand but hyporesponsive to TLR9 ligand (Fig. 2). LC-MS/
MS analyses revealed the difference between TLR9 and 7. 
D34A mutation enhanced Unc93B1 association with TLR7, 
whereas that with TLR9 was suggested to be down-regulated 
by D34A mutation (Fig. 6). Further, D34A mutation en-
hanced TLR7 trafficking but suppressed TLR9 trafficking to 
endolysosomes (Fig. 4). The present study demonstrated that 
Unc93B1 actively biases TLR-dependent nucleic acid sens-
ing against RNA-sensing. Polarization of DC responses against 
TLR7-mediated responses might be understood as a mecha-
nism avoiding hazardous autoimmune reaction, because pre-
vious reports showed that TLR7 is pathogenic in a variety of 
autoimmune diseases (Fig. S6) (12–15).
LC-MS/MS analyses clearly revealed that Unc93B1 asso-
ciation with TLR7/8/13 is up-regulated by D34A mutation 
(Fig. 6, Table S1, and Table S2). In contrast, Unc93B1 associ-
ation with TLR3 or 9 was hard to detect, particularly in 
SILAC (Fig. 6 B and Table S2). Brinkmann et al. clearly dem-
onstrated Unc93B1 association with endogenous TLR3/7/9/13 
in a macrophage cell line, RAW264.7, by using a large num-
ber of cells (4 × 109) (10). The present study, on the other 
hand, focused on BM-DCs and studied Unc93B1 interactions 
with endogenous TLRs in BM-DCs. In this regard, differ-
ences in TLR mRNA expression between RAW264.7 cells 
and BM-DCs are noteworthy in that RAW264.7 cells express 
TLR3/7  much  higher  than  BM-DCs  without  expressing 
TLR8 (Fig. S4 B). Along this line, Brinkmann et al. detected 
Unc93B1 association only with TLR7/9 in a B cell line, A20 
(10). Unc93B1 association with TLRs is likely to change with 
cell types, and it was important to study Unc93B1 association 
DEL/AAA mutations did not influence BM-DC responses to 
lipid A or poly(I:C) (Fig. 7, A and B). L36A and DEL/AAA 
were both as effective as D34A in enhancing TLR7 responses 
(Fig. 7 C). L36A was less effective than D34A in down-regu-
lating TLR9 responses (Fig. 7 D). DEL/AAA completely 
abolished TLR9 responses (Fig. 7 D). As expected from the 
results with Ba/F3 cells (Fig. 1 C), E35A had no effect on 
TLR7/9 responses. These results revealed that the DEL se-
quence in the N-terminal region is important in differentially 
regulating TLR7 and 9 responses.
The N-terminal region of Unc93B1 is expressed  
in TLR7-responsive cells
The results that the N-terminal region of Unc93B1 represses 
TLR7 responses raise a question of how the N-terminal 
portion of Unc93B1 is controlled in TLR7-responsive cells 
like RAW264.7 cells. Alternative splicing or alternative 
transcription start may generate two mRNA isoforms en-
coding full-length or N-terminally truncated Unc93B1. To 
detect  the  mRNA  encoding  the  N-terminally  truncated 
Unc93B1, we conducted RT-PCR amplifying the 5 end of 
Unc93B1 mRNA by using oligo-capped cDNA (30). Only 
a single isoform of Unc93B1 mRNA was detected, and no 
difference was seen between TLR7-responsive RAW264.7 
cells and TLR7-unresponsive Ba/F3 cells (Fig. S5). Even if 
mRNA encodes only the full-length Unc93B1, Unc93B1 
protein  may  be  proteolytically  cleaved,  generating  the   
N-terminally truncated Unc93B1. TLR7-unresponsive Ba/F3 
cells may be different from TLR7-responsive RAW264.7 
cells in the proteolytic cleavage of Unc93B1. This possibility 
was, however, unlikely, because no difference was seen be-
tween Unc93B1-GFP expressed in Ba/F3 or RAW264.7 
cells (Fig. S1 B). The N-terminal region of Unc93B1 is 
likely to be intact in TLR7-responsive cells. The truncated 
Unc93B1 cDNA obtained in this case was probably derived 
from incomplete cDNA synthesis. It has to be noted that the 
cDNA library used in this study also contained the full-
length Unc93B1 cDNA.
Figure 5.  D34A Unc93B1 mutant is not impaired in association with TLR3, 7, and 9. WT, D34A, or H412R Unc93B1 was expressed in Ba/F3 cells 
expressing TLR3, 7, 9, or 4, as indicated in the figure. TLRs were tagged with flag and his, whereas Unc93B1 was tagged with GFP. These cells were sub-
jected to immunoprecipitation and immunoprobing with anti-flag (for immunoprecipitation of TLR), anti-his (for immunoprobing TLR), or anti-GFP anti-
body (for Unc93B1), as indicated in the figure. These experiments were repeated three times and the presented data are shown.1346 Unc93B1 INVERSELY LINKS TOLL-LIKE RECEPTORS 7 AND 9 | Fukui et al.
been identified, the present study suggests the possibility that 
TLR13 responds to microbial RNA. RNA-sensing TLRs 
might compete with DNA-sensing TLR9 for association with 
Unc93B1 in the ER (Fig. S6).
The present study looked for a difference between TLR7-
responsive RAW264.7 and TLR7-unresponsive Ba/F3 cells, 
and found that the N-terminal portion of Unc93B1 represses 
TLR7 responses. These results raise a question of how nega-
tive regulation by the N-terminal region of Unc93B1 is con-
trolled in TLR7-responsive cells like RAW264.7 cells. It is 
possible that Unc93B1 mRNA in TLR7-responsive cells is 
under the control of alternative splicing or alternative tran-
scription start, leading to the lack of the 5 portion encoding 
the N-terminal region. This is, however, unlikely, because 
PCR amplification of the 5 region of Unc93B1 mRNA 
failed to detect such alternative Unc93B1 mRNA isoforms in 
RAW264.7 and Ba/F3 cells (Fig. S5). Another possibility is 
that the N-terminal region of Unc93B1 may be proteolytically 
with TLRs in BM-DCs in the present study. Unfortunately, 
we were unable to obtain as many BM-DCs as RAW264.7 
cells used by the previous study because of the lack of an in 
vitro DC line. However, semiquantitative analyses with LC-
MS/MS suggested that D34A mutation weakens Unc93B1 
association with TLR9 (Fig. 6 A and Table S1). This finding 
is consistent with the results that D34A mutation down-reg-
ulated TLR9 trafficking and TLR9 responses in BM-DCs 
(Figs. 2 and 4). Down-regulation of TLR9 responses and 
trafficking is not explained by up-regulation of Unc93B1 as-
sociation  with  TLR7/8/13,  suggesting  that  strengthened 
Unc93B1 association with TLR7/8/13, in turn, down-regu-
lates that with TLR9. Although a ligand for TLR13 has not 
Figure 6.  D34A mutation up-regulates Unc93B1 association with 
TLR7/8/13. (A and B) D34A or WT Unc93B1-GFP was expressed in  
BM-DCs from 3d mice. Unc93B1-GFP was immunoprecipitated by anti-GFP 
mAb, and precipitates were analyzed on LC-MS/MS analyses. (A) For label-
free semiquantitative analysis, the XIC values of each peptide from 
Unc93B1 and TLR3, 7, 8, 9, and 13 were calculated directly by the 
MSQuant program. Immunoprecipitated peptides from TLR3, 7, 8, 9, and 13 
associated with D34A or WT Unc93B1 in BM-DCs were compared by  
dividing the value from D34A by that from WT in each peptide. The num-
ber of analyzed peptides and the mean ratio are shown. Detailed results 
are shown in Table S1. The experiments were repeated twice and similar 
results were obtained. (B) For SILAC experiments, BM-DCs expressing WT 
or D34A Unc93B1-GFP were cultured in the presence of normal lysine 
and arginine or the heavy isotopic forms of these aa (experiment 1), or of 
arginine or the heavy isotopic form of arginine (experiment 2), respec-
tively. The XIC values of each peptide from Unc93B1 and TLR7 and 9 were 
calculated using the MSQuant program. The ratios represent the relative 
abundance of the heavy to the light peptide, indicating the binding ratio 
(D34/WT). The number of analyzed peptides, the mean ratio, and the SD 
are shown. Detailed information for each peptides is shown in Table S2. 
These experiments were repeated twice and all of the data are shown.
Figure 7.  D34 and L36 are required for differential regulation of 
TLR7 and 9 in BM-DCs. (A–D) DCs from 3d mice were transduced by 
retroviral vector encoding GFP (3dDC; white bars), WT Unc93B1-GFP (WT; 
blue bars), D34A Unc93B1-GFP (D34A; red bars), E35A Unc93B1-GFP (E35A; 
gray bars), L36A Unc93B1-GFP (L36A; black bars), or DEL/AAA Unc93B1-
GFP (DEL/AAA; yellow bars). These DCs were stimulated with (A) lipid A,  
(B) poly(I:C), (C) loxoribine, or (D) CpG-B at the indicated concentrations. Pro-
duction of IL-12p40 (left) and IL-6 (right) was determined by ELISA. The 
results are represented by mean values with SD from triplicate wells. These 
experiments were repeated twice and the represented data are shown.JEM VOL. 206, June 8, 2009 
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TLR4/MD-2. Finally, self-derived DNA and RNA derived 
from  dead  cells  are  also  able  to  simultaneously  stimulate 
TLR7 and 9 expressed in B cells or DCs during inflamma-
tion. Concurrent activation of TLR7 and 9 is likely to occur 
in infectious and noninfectious diseases.
Type I IFNs are tightly regulated cytokines, and overex-
pression of type I IFN can be detrimental to the host. Highly 
elevated levels of type I IFN have been implicated as etiologic 
for systemic lupus erythematosus (44). Increased serum type I 
IFN has been shown to correlate directly with disease severely 
in human systemic lupus erythematosus (45). TLR7 and 9 are 
known to be strong promoters of type I IFN secretion from 
DCs. If TLR7 and 9 are both activated without any limit, 
type I IFN is likely to be excessively produced, predisposing 
to autoimmune diseases. DCs may inversely link TLR7 with 
TLR9 to keep the production of type I IFN under the control 
and to avoid excessive production of type I IFN.
Previous reports have revealed pathogenic roles for TLR7 
in lupus nephritis. Overexpression of TLR7 in the Yaa or 
transgenic mice predisposes to lupus nephritis (12, 13), whereas 
the lack of the TLR7 gene ameliorates disease progression in 
lupus-prone mice (14, 15). DCs need to have a mechanism 
limiting TLR7 activation. Overexpression of TLR9 inhibits 
TLR7 responses (22). Another mechanism has been revealed 
in this study that TLR7 responsiveness was down-regulated 
by the N-terminal cytoplasmic portion of Unc93B1. Given 
the reciprocal link between TLR7 and 9, Unc93B1 balances 
TLR7 and 9 to warrant sufficient TLR7 responsiveness with-
out detrimental autoimmune responses (Fig. S6).
TLR7/9 agonists and antagonists are being developed for 
therapeutic intervention in infectious diseases, cancer, aller-
gic diseases, and autoimmune diseases (46–48). The present 
study showed that the effect of these agonists/antagonists has 
to be carefully evaluated, because specific agonists/antago-
nists for TLR7 or 9 may have an indirect effect on TLR9 or 7, 
respectively. Such indirect effects may cause unexpected   
action on diseases. Given that TLR7 hyperresponsiveness 
and TLR9 hyporesponsiveness both predispose to autoim-
mune diseases (12–14), the N-terminal portion of Unc93B1 
may be a novel target for a therapeutic intervention in auto-
immune diseases that modulates the balance between TLR7 
and 9 in DCs.
MATERIALS AND METHODS
Reagents  and  antibodies.  CpG-B  (5-TCCATGACGTTCCTGAT-
GCT-3) was synthesized by Hokkaido System Science. Lipid A was pro-
vided  by  K.  Fukase  (Osaka  University,  Osaka,  Japan).  Loxoribine, 
imiquimod, and poly(I:C) were purchased from InvivoGen. Recombinant 
mouse stem cell factor, mouse IL-3, and mouse IL-6 were purchased from 
PeproTech. Recombinant mouse GM-CSF was purchased from R&D Sys-
tems. Texas red–conjugated ER-tracker and Texas red–conjugated Lyso-
tracker  were  purchased  from  Invitrogen.  PE-conjugated  anti-CD11c 
antibody was purchased from eBioscience. Rabbit anti-GFP antibody was 
purchased from MBL International. The affinity-purified rat mAbs against 
6xHis (clone 333) and GFP (clone FM264) were generated in our labora-
tory. Anti-flag antibody–conjugated beads, G418, and puromycin were pur-
chased  from  Sigma-Aldrich.  Anti-HA  antibody–conjugated  beads  and 
anti-HA antibody (clone 3F10) were purchased from Roche.
cleaved off in TLR7-responsive cells, as was TLR9 (26, 31, 32). 
Unc93B1-GFP expressed in RAW264.7 cells, however, did 
not appear to be truncated when compared with that in Ba/F3 
cells (Fig. S1 B, compare left and right lanes).
The N-terminal region of Unc93B1 is left uncleaved in 
TLR7-responsive cells, and is likely to be inactivated by an as 
yet unknown mechanism. In this regard, it is noteworthy that 
the DEL (34-36) sequence required for repressing TLR7 re-
sponse agrees with the motif (D/E-X-) that is known to 
interact with the class III PDZ (PDS95/dlg/ZO-1) domain 
(33). Requirement for 34D and 36L but not 35E is consistent 
with the lack of any restriction (X) in the second aa in the D/
E-X- motif (Fig. 1 C; Fig. 7; and Fig. S2). The class III PDZ 
domain is not found in TLRs, suggesting that DEL (34-36) is 
required for interaction with a non-TLR, class III PDZ do-
main–containing molecule, which may have a role in con-
trolling the activity of the N-terminal region of Unc93B1.
Although not experimentally proven yet, the lack of an 
N-terminal hydrophobic signal sequence suggests that the   
N-terminal region of Unc93B1 faces the cytosol. The N ter-
minus of Unc93B1 may have a role not only in differential 
association of Unc93B1 with TLR7 and 9 but also in modu-
lating signaling pathways downstream of TLR7 or 9. In this 
regard, it is of note that TLR9-dependent RANTES pro-
duction was more resistant to D34A mutation than produc-
tion of IL-12 or IL-6 (Fig. 2 D). It will be interesting to see, 
in future studies, the effect of D34A mutation in signaling 
pathways downstream of TLR7 and 9.
Immune cells such as DCs or macrophages express multi-
ple TLRs, which are concomitantly activated in response to 
pathogens, because single microbes or viruses express a vari-
ety of TLR ligands. Given that multiple TLRs simultane-
ously respond to pathogens, their distribution and activation 
need to be orchestrated for optimal immune responses. In-
deed, a synergistic relationship between TLR4/MD-2 and 
TLR7/9 has been recently reported in the triggering of   
IL-12 and other Th1-promoting cytokines by DCs (34, 35). 
TLR3 and TLR7/9 also show synergistic responses (36–38). 
Dual recognition of Mycobacterium tuberculosis by TLR2 and 9 
is required for efficient responses (39). HSVs were reported 
to be recognized by both TLR2 and 9 (40). We have shown 
in this study that multiple TLRs in DCs are connected not 
only by these additive or synergistic links but also by an in-
versely regulated link.
Simultaneous triggering of TLR7 and 9 may be thought 
to be a less likely combination in viral infection, as viruses are 
classified into either DNA or RNA viruses. The DNA ge-
nomes from viruses like HSV-1, HSV-2, and mouse CMV 
are rich in CpG motifs, which activates TLR9 (40), whereas 
TLR7 recognizes single-stranded RNA from RNA viruses 
like influenza and vesicular stomatitis virus (41). Concurrent 
infection with a DNA virus and an RNA virus is a rare event. 
However, a DNA virus like herpesvirus has been recently 
suggested to stimulate both TLR7 and 9 (42). DNA and 
RNA derived from bacterial pathogens are reported to stim-
ulate TLR3, 7, and 9 (43), as well as cell-surface TLR2 and 1348 Unc93B1 INVERSELY LINKS TOLL-LIKE RECEPTORS 7 AND 9 | Fukui et al.
were obtained in each library. These cDNA libraries were packaged and trans-
duced into Ba/F3 cells expressing CD14/TLR4/MD-2, TLR7-flag, and 
pNF-B–hrGFP. These cells were stimulated with 100 µM loxoribine for   
24 h, and GFP-positive cells were selected by sorting with flow cytometry. Re-
covered cells were allowed to grow and subjected to a second sorting. After the 
third sorting, cDNAs derived from the library were recovered from genomic 
DNA by PCR and retransduced to confirm the complementation activity.
Transduction into BM-DCs. BM cells were isolated from WT or 3d mu-
tant mice that had been injected intraperitoneally with 5 mg 5-fluorouracil. 
After 48 h of culture, cells were transduced with retroviral vector containing 
the puromycin resistance gene on two successive days. After the second 
transduction, cells were washed and cultured in the presence of 10 ng/ml 
GM-CSF. During BM-DC induction, 2 µg/ml puromycin was included to 
enrich BM-DCs expressing Unc93B1. For double selection, 1 µg/ml puro-
mycin and 200 µg/ml neomycin were included.
LC-MS/MS analyses. BM-DCs expressing WT or D34A Unc93B1-GFP 
were subjected to lysis with digitonin and immunoprecipitation with anti-
GFP mAb. Bound molecules released by acid elution were digested with 
trypsin directly in the solution, desalted, and concentrated to a volume of 
20 µl. The samples were then injected into a direct nanoflow LC system 
(Dina; KYA Technologies), and sprayed into a quadrupole time-of-flight 
tandem mass spectrometer (QSTAR Elite; Applied Biosystems).
Label-free  semiquantitative  analysis  using  the  XIC-based  peptide 
quantification.  Database  searches  were  performed  with  Mascot  (http://
www.matrixscience.com). The score shown in the tables is the Mascot ion 
score representing the quality of the match of the identified peptide. The XIC 
is a measure that is proportional to the peptide’s abundance. The XIC values 
of each peptide from Unc93B1 and TLR3, 7, 8, 9, and 13 were calculated di-
rectly  without  isotope  labeling  by  using  the  MSQuant  program  (http://
msquant. sourceforge.net/). The XIC values were retrieved directly for the 
corresponding peptides’ m/z signals between the two states. The values of 
peptides derived from BM-DCs expressing D34A Unc93B1-GFP were di-
vided with the values from WT Unc93B1 to compare the binding ratio. The 
mean and SD were calculated for each protein (Tables S1 and S2).
SILAC. BM-DCs expressing WT or D34A Unc93B1-GFP were grown in 
the presence of normal lysine and arginine (unlabeled) or heavy isotopic 
forms of these aa (labeled) in experiment 1 (Fig. 6). In experiment 2, only 
arginine was labeled. BM-DCs were cultured for 11 d (51) and subjected to 
lysis with digitonin, and lysates from labeled and unlabeled cells were com-
bined in a 1:1 ratio according to their protein concentrations estimated by 
BCA assay (Thermo Fisher Scientific). The mixed lysate was immunopre-
cipitated with anti-GFP mAb. SILAC methods were used (52).
Detection of full-length mRNA. Total RNA from Ba/F3 or RAW264.7 
cells were prepared with RNAeasy kit according to the manufacturer’s in-
struction. Total RNA was subjected to oligo capping, as previously described 
(30). Oligo-capped full-length mRNA were reverse transcribed with the 
Super Script II RT kit with an oligo-dT primer. Synthesized cDNA were 
used as the PCR template. The PCR reaction was performed by a forward 
primer on oligo capping (5-TCGAGTCGGCCTTGTTGGCCTACTG-3) 
and a reverse primer on Unc93B1 (5-TGGCGTAAGCGAAAGTCACG-
CACGTG-3; 1,063–1,038). The expected size is 1,100 bp.
Online supplemental material. Fig. S1 shows the expression of full-length 
and truncated Unc93B1. Fig. S2 depicts the effect of N-terminal deletion 
of Unc93B1 on TLR7 responses. Fig. S3 shows expression of Unc93B1-
GFP and CD11c in BM-DCs. Fig. S4 depicts TLR mRNA expression in 
BM-DCs, Ba/F3 cells, and RAW264.7 cells. Fig. S5 shows no difference in 
Unc93B1 mRNA transcription start between Raw264.7 and Ba/F3 cells.   
Fig. S6 depicts RNA- versus DNA-sensing in DCs controlled by a Unc93B1-
dependent inverse link between TLR7 and 9. Table S1 shows the XIC-based 
Mice and cell lines. WT C57BL/6 mice were purchased from Japan SLC, 
and 3d mice were obtained from K. Tabeta (Niigata University, Niigata, Ja-
pan). Mice were kept under specific pathogen-free conditions in the animal 
center at the University of Tokyo. The experiments were performed ac-
cording to institutional ethical guidelines for animal experiments at the Uni-
versity of Tokyo. All animal experiments were approved by the Animal Care 
and Use Committee of the University of Tokyo. Ba/F3 and RAW 264.7 
cells were maintained as previously described (49).
Plasmid constructs. The epitopes (flag-6xHis, GFP, mCherry, or HA) 
were tagged to the C termini of mouse TLR3, 7, and 9, and Unc93B1, as 
indicated in the figures. They were generated by PCR and cloned into ret-
roviral pMX, pMXpuro, or pMXneo vectors. Mouse TLR4, MD-2, CD14, 
NF-B–hrGFP, cathepsin B, and cathepsin L were cloned into expression 
vectors as previously described (19). Truncated Unc93B1 and aa-mutated 
Unc93B1 were generated by the QuickChange Site-Directed Mutagenesis 
Kit (Agilent Technologies) and cloned into C-terminally tagged pMX or 
pMXpuro vectors. The primers for aa mutant Unc93B1 were constructed to 
change their DNA as follows: H412R, CAC (His) to CGC (Arg); D34A, 
GAC (Asp) to GCC (Ala); E35A, GAA (Glu) to GCA (Ala); and L36A, 
CTC (Leu) to GCC (Ala). The DEAA mutant was generated by sequential 
mutation of D34A and E35A. The DEL/AAA mutant was generated by 
combining the three mutations.
Retroviral transduction. pMX, pMXpuro, and pMXneo vectors were 
transfected into Plat-E packaging cells with FuGene6 (Roche). After 2 d of 
incubation, supernatants were obtained as virus suspensions. Cells were in-
fected by the mixture of virus suspension and DOTAP (Roche).
ELISA. Cytokines in culture supernatants were measured with ELISA kits 
(R&D Systems).
Quantitative real-time PCR. Total RNA were prepared by ISOGEN 
(NIPPON GENE) or RNAeasy (QIAGEN) and reverse transcribed with 
ReverTra Ace (TOYOBO) or the Super Script II RT kit (Invitrogen). 
Quantitative real-time PCR analyses were performed using 7300 Fast Real-
Time PCR System (Applied Biosystems), as previously described (50).
Immunofluoresence staining and confocal microscopy. DCs were in-
cubated  on  a  poly–l-lysine–coated  glass-bottom  dish  overnight  to  allow 
them to adhere. Cells were stimulated by 1 µM CpG-B or 5 µg/ml imiqui-
mod for 60 min. After stimulation, cells were incubated with Texas red–con-
jugated ER-tracker or Lysotracker for staining ERs or lysosomes, respectively. 
Nonstimulated cells were stained the same. Stained cells were washed two 
times with HBSS. ER-tracker–stained cells were fixed with 3.7% formalde-
hyde in PBS for 10 min at room temperature. Lysotracker-stained cells were 
not fixed and suspended in 10% FCS containing PBS. Confocal microscopy 
was performed on a confocal microscope (LSM510; Carl Zeiss, Inc.).
Immunoprecipitation. Cells were collected and washed with HBSS two 
times. Washed cells were lysed with 1% digitonin lysis buffer in Fig. 4 (150 mM 
NaCl, 50 mM Tris/HCl [pH 7.4], 5 mM EDTA [pH 8], 10 µg/ml leu-
pepsin, 10 µg/ml aprotinin, and 1 mM PMSF) or 0.5% Triton lysis-washing 
buffer in Fig. S2 (137 mM NaCl, 20 mM Tris/HCl [pH 7.4], 1 mM EDTA 
[pH 8], 10 µg/ml leupepsin, 10 µg/ml aprotinin, 1 mM PMSF). Lysates 
were rotated with antibody-conjugated beads overnight. Beads were washed 
with 0.1% digitonin washing buffer (150 mM NaCl, 50 mM Tris/Hcl [pH 7.4], 
5 mM EDTA [pH 8]) three times. Immunoprecipitates were subjected   
to SDS-PAGE after boiling in SDS-PAGE sample buffer (125 mM Tris/HCl 
[pH 6.8], 20% glycerol, 4% SDS, 10% 2-ME, 0.005% bromophenol blue).   
After electrophoresis, samples were transferred to PVDF membrane and   
subjected to immunoblotting.
Complementation cloning. cDNA was synthesized from RAW264.7 cells 
and cloned into a retrovirus vector. About 2 million independent colonies JEM VOL. 206, June 8, 2009 
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